Counterfeit drugs: a global problem

24 March 2016  •  Author(s): Victoria White, European Pharmaceutical Review

In a recent issue of European Pharmaceutical Review, David Shore from Pfizer discussed his company’s progress in combatting the illegal trade of counterfeit drugs.

counterfeit drugs

The trade in fake drugs is considerable; according to Pfizer’s own company records, more than 200 million counterfeit doses of Pfizer product alone have been intercepted since 2004. Indeed, the pharmaceutical industry takes counterfeiting very seriously. Last month, at PharmaPack Europe, the issue was chief among the event’s themes.

We’ve created an infographic on counterfeit drugs, highlighting some of the actions taken to counter this global problem:

counterfeit drugs

Find out more about counterfeit drugs

One response to “Counterfeit drugs: a global problem”

  1. For direct traceability and authentication of your key molecules, please visit our website (supply chain) and do not hesitate to contact us at anytime. Based on your global situation and/or specific needs, we will propose you the most accurate solution to avoid potential counterfeiting problems. Thank you!

Leave a reply


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...